Combining two or more active molecules into a hybrid structure is a popular strategy in the design of new therapeutic agents and prior approaches aiming to improve the targeting and anticancer activity of platinum and ruthenium complexes by modifying them with metabolites revealed significant benefits . Conjugating metal complexes to nucleobases, nucleosides and nucleotides afforded compounds with a wide range of applications as for example potential anticancer agents . An important effort was invested in the development of various metallocene-nucleobase hybrids and research was further extended to other organometallic derivatives , some relevant examples being presented in Figure .